Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Jean-Philippe Collet , Jochem Wouter van Werkum Added: 3 years ago
Antiplatelet therapy is the standard of care for patients with acute coronary syndromes (ACS) and/or patients undergoing percutaneous coronary intervention (PCI) with stenting.1–3 Plaque rupture and/or iatrogenic vascular damage during PCI would normally result in the development of intravascular thrombus. Findings across multiple investigations consistently demonstrate the effectiveness of dual… View more
Author(s): Paul A Gurbel , David Kandzari Added: 3 years ago
The rare but catastrophic occurrence of stent thrombosis, in particular 'late' stent thrombosis, in association with deployment of drug-eluting stents has focused attention on the adequacy of the current dual anti-platelet regimen of aspirin and clopidogrel. Stent thrombosis is due to multiple factors. These include, specific stent features (delayed healing or polymer hypersensitivity),… View more
Author(s): Thomas O Bergmeijer , Jochem Wouter van Werkum , Udaya S Tantry , et al Added: 3 years ago
Coronary angiography and subsequent percutaneous coronary intervention (PCI) is the appropriate treatment in many patients with moderate- and high-risk acute coronary syndromes (ACS). As ACS and complications after PCI are primarily platelet-driven, adequate antiplatelet therapy is of utmost importance in patients with ACS and after coronary stent implantation. The main antiplatelet agents… View more
Author(s): Hector M Garcia-Garcia , Patrick W Serruys Added: 3 years ago
To date, cardiologists have alleviated the symptoms of patients with significant lesions in the coronary angiography by stenting or coronary artery bypass grafting. While normal-looking coronary segments in angiography have been regarded as ‘disease-free’ and mild/moderate stenoses as ‘non-treatable’, today that we know that from these non-significantly diseased areas may potentially arise acute… View more
Author(s): Julius Nikorowitsch Added: 3 days ago
EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).The substudy consisted of 2534 patients from… View more
Author(s): Jason N Dungu Added: 3 years ago
Amyloidosis is a condition characterised by accumulation of pathologic fibrillar proteins in organs causing dysfunction.1 Several protein precursors have been shown to cause amyloidosis.2 Cardiac amyloidosis, when waxy, starch-like deposits infiltrate the heart, is most commonly secondary to the accumulation of amyloid fibrils derived from immunoglobulin light chains (AL) or transthyretin (ATTR)… View more
Author(s): Suzanne J Baron , Robert P Giugliano Added: 3 years ago
Coronary artery disease remains the leading cause of death in the US and worldwide. Although the incidence of death due to coronary artery disease has declined over the last several years, the prevalence of coronary artery disease remains high, with the American Heart Association (AHA) estimating that over 81 million Americans suffer from cardiovascular disease and 2,200 people dying every day of… View more
Job title: Editor-in-Chief, US Cardiology Review
Dr Gogas has more than 10 years of clinical and research experience in cardiology/interventional cardiology. He is current faculty at Nanjing University in China and formerly held a position in the Division of Cardiology of Emory University School of Medicine at the rank of Instructor of Medicine. He received his PhD from Erasmus University, Rotterdam, in 2014 under the mentorship of Prof Patrick… View more